[go: up one dir, main page]

Wakamoto et al., 2008 - Google Patents

Alpha-methyl-l-tryptophan positron emission tomography in epilepsy with cortical developmental malformations

Wakamoto et al., 2008

Document ID
2601410656504406628
Author
Wakamoto H
Chugani D
Juhász C
Muzik O
Kupsky W
Chugani H
Publication year
Publication venue
Pediatric neurology

External Links

Snippet

Preliminary studies suggest that alpha [11C] methyl-l-tryptophan positron emission tomography can detect the epileptic focus within malformations of cortical development. We determined the sensitivity and specificity of alpha-[11C] methyl-l-tryptophan positron …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions

Similar Documents

Publication Publication Date Title
Perosa et al. Perivascular space dilation is associated with vascular amyloid-β accumulation in the overlying cortex
Sullivan et al. Oligodendrocyte lineage and subventricular zone response to traumatic axonal injury in the corpus callosum
Papadopoulos et al. Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis
Jackson et al. Detection of hippocampal pathology in intractable partial epilepsy: increased sensitivity with quantitative magnetic resonance T2 relaxometry
Stimmler et al. Magnetic resonance imaging of the brain in neuropsychiatric systemic lupus erythematosus
Mueller et al. Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Auer et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study
Poulin et al. Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity
Kashihara et al. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson’s disease
Fedi et al. α-[11C]-Methyl-L-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency
Wakamoto et al. Alpha-methyl-l-tryptophan positron emission tomography in epilepsy with cortical developmental malformations
Buzzi et al. Loss of cortical GABA terminals in Unverricht–Lundborg disease
Janz et al. Early tissue damage and microstructural reorganization predict disease severity in experimental epilepsy
Duarte et al. Multivariate pattern analysis reveals subtle brain anomalies relevant to the cognitive phenotype in neurofibromatosis type 1
Werring Cerebral microbleeds: pathophysiology to clinical practice
Schulz et al. Neuropathies in the setting of neurofibromatosis tumor syndromes: complexities and opportunities
Park et al. Cerebellar white matter changes in patients with newly diagnosed partial epilepsy of unknown etiology
Takahashi et al. Prevalence of large cavum septi pellucidi and its relation to the medial temporal lobe structures in schizophrenia spectrum
Miller et al. Advances in imaging to support the development of novel therapies for multiple sclerosis
Pirpamer et al. Periventricular magnetisation transfer abnormalities in early multiple sclerosis
Ueda et al. Glymphatic system dysfunction in mood disorders: evaluation by diffusion magnetic resonance imaging
Lönnfors-Weitzel et al. T2-relaxometry predicts outcome of DBS in idiopathic Parkinson's disease
Rother et al. Characterization and quantification of alcohol‐related polyneuropathy by magnetic resonance neurography
Yang et al. Diffusion basis spectrum imaging measures anti-inflammatory and neuroprotective effects of fingolimod on murine optic neuritis
Brinar et al. Challenges in multiple sclerosis; how to define occurence of progression